Laila Hübbert

Renske Altena, Laila Hübbert, Narsis A. Kiani, Yvonne Wengstrom, Jonas Bergh, Elham Hedayati (2021) Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer Cardio-Oncology, Vol. 7, Article 20

Elham Hedayati, Antroula Papakonstantinou, Sofie A M Gernaat, Renske Altena, Judit S. Brand, Joakim Alfredsson, Nirmala Bhoo-Pathy, Jeorg Herrmann, Cecilia Linde, Ulf Dahlström, Jonas Bergh, Laila Hübbert (2020) Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based study European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 6, p. 147-155

E. Hedayati, A. Papakonstantinou, A. Månsson-Broberg, J. Bergh, Laila Hübbert, R. Altena (2020) Approaches to management of cardiovascular morbidity in adult cancer patients: cross-sectional survey among cardio-oncology experts Cardio-oncology (London, England), Vol. 6

Kristjan Karason, Lars H. Lund, Magnus Dalen, Erik Bjorklund, Karl Grinnemo, Oscar Braun, Johan Nilsson, Henriette van der Wal, Jonas Holm, Laila Hübbert, Krister Lindmark, Barna Szabo, Erik Holmberg, Goran Dellgren (2020) Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial European Journal of Heart Failure, Vol. 22, p. 739-750

Antroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, Per Malmstrom, Elham Hedayati, Guenther Steger, Michael Untch, Laila Hübbert, Hemming Johansson, Mats Hellstrom, Michael Gnant, Sibylle Loibl, Richard Greil, Volker Moebus, Theodoros Foukakis, Jonas Bergh (2020) Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial Cancer

Publications